These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 15124142)

  • 1. Multiple myeloma: the role of transplant and novel treatment strategies.
    Kaufman J; Lonial S
    Semin Oncol; 2004 Apr; 31(2 Suppl 4):99-105. PubMed ID: 15124142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy strategies for multiple myeloma: current status.
    Gisslinger H; Kees M
    Wien Klin Wochenschr; 2003 Aug; 115(13-14):451-61. PubMed ID: 13677263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma.
    Hussein MA
    Oncologist; 2002; 7 Suppl 1():20-9. PubMed ID: 11961206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding novel therapeutic agents for multiple myeloma.
    Tariman JD
    Clin J Oncol Nurs; 2003; 7(5):521-8. PubMed ID: 14603548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of drug therapy for multiple myeloma.
    Saunders G
    J Oncol Pharm Pract; 2005 Sep; 11(3):83-100. PubMed ID: 16390597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma.
    Kalmadi SR; Hussein MA
    Acta Haematol; 2006; 116(1):1-7. PubMed ID: 16809883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted therapy in multiple myeloma.
    Chng WJ; Lau LG; Yusof N; Mow BM
    Cancer Control; 2005 Apr; 12(2):91-104. PubMed ID: 15855892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis and therapy of multiple myeloma.
    Palumbo A; Cerrato C
    Korean J Intern Med; 2013 May; 28(3):263-73. PubMed ID: 23682217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New drugs in multiple myeloma.
    Berenson JR; Yellin O
    Curr Opin Support Palliat Care; 2008 Sep; 2(3):204-10. PubMed ID: 18685422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New treatments for multiple myeloma.
    Richardson PG; Schlossman R; Hideshima T; Anderson KC
    Oncology (Williston Park); 2005 Dec; 19(14):1781-92; discussion 1792, 1795-7. PubMed ID: 16506632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple myeloma: increasing our treatment options.
    Alsina M
    Cancer Control; 2003; 10(5):357-8. PubMed ID: 14581889
    [No Abstract]   [Full Text] [Related]  

  • 13. Bortezomib treatment followed by a second non-myeloablative allogeneic stem cell transplant in two previously autografted patients with multiple myeloma relapse.
    Mattei D; Mordini N; Vigna Taglianti R; Bruno B; Rapezzi D; Gallamini A
    Haematologica; 2005 Jun; 90(6):861-2. PubMed ID: 15951306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapy of multiple myeloma.
    Kyle RA
    Hematology; 2012 Apr; 17 Suppl 1():S125-8. PubMed ID: 22507799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance treatment in multiple myeloma.
    Harousseau JL
    Ann Oncol; 2008 Jun; 19 Suppl 4():iv54-5. PubMed ID: 18519405
    [No Abstract]   [Full Text] [Related]  

  • 16. The emerging role of novel therapies for the treatment of relapsed myeloma.
    Richardson PG; Hideshima T; Mitsiades C; Anderson KC
    J Natl Compr Canc Netw; 2007 Feb; 5(2):149-62. PubMed ID: 17335684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel agents to improve outcome of allogeneic transplantation for patients with multiple myeloma.
    Kortüm M; Knop S; Einsele H
    Future Oncol; 2011 Jan; 7(1):135-43. PubMed ID: 21174544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frontline therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials.
    Yaqub S; Ballester G; Ballester O
    Cancer Invest; 2013 Oct; 31(8):529-37. PubMed ID: 24083815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple myeloma.
    Kyle RA; Rajkumar SV
    N Engl J Med; 2004 Oct; 351(18):1860-73. PubMed ID: 15509819
    [No Abstract]   [Full Text] [Related]  

  • 20. [Bortezomib plus dexamethasone treatment followed by reduced-intensity allogeneic stem cell transplantation for multiple myeloma refractory to high-dose chemotherapy with autologous transplantation].
    Hayashi T; Yasui H; Kawakami K; Ikeda H; Takahashi F; Kobayashi T; Nishimura S; Ishida T; Imai K; Shinomura Y
    Rinsho Ketsueki; 2011 Mar; 52(3):136-41. PubMed ID: 21471701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.